VIDEO: Combination boosts survival for resected pancreatic cancer

CHICAGO – Lead author Dr. John P. Neoptolemos presented results of the European Study Group for Pancreatic Cancer’s Trial 4 (ESPAC-4), results he said would likely change the standard of care for resected pancreatic cancer.

Adding capecitabine to gemcitabine as adjuvant therapy prolonged survival among patients who have undergone resection of pancreatic cancer with curative intent, he reported at the annual meeting of the American Society of Clinical Oncology.

In an interview at the meeting, Dr. Neoptolemos discusses the efficacy results, toxicities and implications for practice. Dr. Neoptolemos is chair of surgery in the department of molecular and clinical cancer medicine at the University of Liverpool, United Kingdom.

CHICAGO – Lead author Dr. John P. Neoptolemos presented results of the European Study Group for Pancreatic Cancer’s Trial 4 (ESPAC-4), results he said would likely change the standard of care for resected pancreatic cancer.

Adding capecitabine to gemcitabine as adjuvant therapy prolonged survival among patients who have undergone resection of pancreatic cancer with curative intent, he reported at the annual meeting of the American Society of Clinical Oncology.

In an interview at the meeting, Dr. Neoptolemos discusses the efficacy results, toxicities and implications for practice. Dr. Neoptolemos is chair of surgery in the department of molecular and clinical cancer medicine at the University of Liverpool, United Kingdom.

CHICAGO – Lead author Dr. John P. Neoptolemos presented results of the European Study Group for Pancreatic Cancer’s Trial 4 (ESPAC-4), results he said would likely change the standard of care for resected pancreatic cancer.

Adding capecitabine to gemcitabine as adjuvant therapy prolonged survival among patients who have undergone resection of pancreatic cancer with curative intent, he reported at the annual meeting of the American Society of Clinical Oncology.

In an interview at the meeting, Dr. Neoptolemos discusses the efficacy results, toxicities and implications for practice. Dr. Neoptolemos is chair of surgery in the department of molecular and clinical cancer medicine at the University of Liverpool, United Kingdom.